PAI-1 Inhibition in experimental venous thrombosis

Authors

• Maxim E. Shaydakov, University of Michigan - Ann Arbor
• Cory D. Emal, Eastern Michigan University
• Joshua P. Rainey, University of Utah
• Daniel A. Lawrence, University of Michigan - Ann Arbor
• Jose A. Diaz, University of Michigan - Ann Arbor

Document Type

Article

Publication Date

2026

Department/School

Chemistry

Publication Title

Phlebology

Abstract

Background A novel PAI-1 inhibitor, MDI-2268, has been recently developed. The aim of the study was to evaluate the antithrombotic effects and safety of the MDI-2268 in acute venous thrombosis (VT) in vivo. Methods C57BL/6 mice, 10-12 weeks old, weighing 20-25g, were used in electrolytic model of VT (EIM). MDI-2268 1.5 mg/kg (Group 1), MDI-2268 3 mg/kg (Group 2), enoxaparin 7.3 mg/kg (Group 3), and MDI-2268 1.5 mg/kg plus enoxaparin 1.8 mg/kg (Group 4) were compared to the controls (sham surgery). Animals were sacrificed on Day 2. Thrombus weight and tail bleeding time were measured. Results TW was 6.9 +/- 3.3 (p > .05), 5.5 +/- 1.6 (p = .016), 3.8 +/- 1.3 (p = .032), and 4.8 +/- 2.4 mg (p = .016) for groups 1, 2, 3, and 4, respectively, compared to the controls. Bleeding time was not significantly affected by the MDI-2268. Conclusions MDI-2268 is a novel pro-fibrinolytic agent that demonstrates strong antithrombotic properties without prolongation of bleeding time in this experimental model.

Comments

C. D. Emal is a faculty member in EMU's Department of Chemistry.

Link to Published Version

DOI: 10.1177/02683555261421027

Recommended Citation

Shaydakov, M. E., Emal, C. D., Rainey, J. P., Lawrence, D. A., & Diaz, J. A. (2026). PAI-1 Inhibition in experimental venous thrombosis. Phlebology, 41(8), 735–738. https://doi.org/10.1177/02683555261421027